Recall of Animas insulin pumps listed as Class I
This article was originally published in The Silver Sheet
FDA has categorized an August recall of battery caps used in the Animas OneTouch Ping, 2020, IR1200 and IR1250 insulin pump systems as Class I. The recalled battery caps were losing contact with the insulin pump's battery compartment, causing the pump to reset and temporarily lose power. This could cause either a loss of insulin delivery, resulting in hyperglycemia, or accidental overdosing by the user, resulting in hypoglycemia, FDA notes in its Nov. 20 announcement. Animas sent letters and replacement battery caps to customers from Aug. 18 to Sept. 1, and also sent letters to distributors
You may also be interested in...
Dispatches from a world turned upside down include FDA expressing confidence in Chinese manufacturers – to make their GDUFA payments; projections of drug shortages for ventilator patients; and the launch of new hydroxychloroquine studies.
A Phase III trial testing the antibody-drug conjugate sacituzumab govitecan was stopped early for efficacy, boding well for the BLA pending at the US FDA.
Deal Snapshot: Six companies seek to collect convalescent plasma from COVID-19 survivors to quickly develop hyperimmune immunoglobulin therapy for serious complications of the virus.